BC Extra | Sep 16, 2019
Company News

Lundbeck enters migraine race with $2B takeout of Alder

Lundbeck will add a CGRP inhibitor to its neurology pipeline by buying Alder for just shy of $2 billion, but the Scandinavian pharma will be playing catch-up as eptinezumab will likely be fourth among drugs...
BC Innovations | Jan 23, 2019
Distillery Therapeutics


INDICATION: Migraine In vitro and rat studies identified a mAb against the ADCYAP1-derived peptides PACAP-38 and PACAP-27 that could help treat migraine. In vitro screening of B cell cultures of PACAP-38-immunized rabbits for mAbs that...
Items per page:
1 - 2 of 2